Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its Hold rating reiterated by Morgan Stanley with a $87.00 price target

Analyst Ratings For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Story continues below

Today, Morgan Stanley reiterated its Hold rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a price target of $87.00.

There are 14 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is Buy with a consensus target price of $148.2941 per share, a potential 64.61% upside.

Some recent analyst ratings include

  • 9/28/2018-Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its Hold rating reiterated by Morgan Stanley with a $87.00 price target
  • 9/13/2018-Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its Buy rating reiterated by Needham & Company LLC with a $152.00 price target
  • 9/13/2018-Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its Buy rating reiterated by Stifel Nicolaus with a $117.00 price target
  • 9/4/2018-Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its Buy rating reiterated by Cowen with a $147.00 price target


    About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
    Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

    Recent Trading Activity for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
    Shares of Alnylam Pharmaceuticals, Inc. closed the previous trading session at 90,09 −1,24 1,36 % with 86.95 shares trading hands.

    An ad to help with our costs